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CA 91125, United States 
Abstract 
ATPases Associated with Diverse Cellular Activity (AAA ATPase) are essential enzymes found 
in all organisms. They are involved in various processes such as DNA replication, protein 
degradation, membrane fusion, microtubule serving, peroxisome biogenesis, signal transduction, 
and the regulation of gene expression. Due to the importance of AAA ATPases, several 
researchers identified and developed small-molecule inhibitors against these enzymes. We 
discuss six AAA ATPases that are potential drug tarets and have well-developed inhibitors. We 
compare available structures that suggest significat differences of the ATP binding pockets 
among the AAA ATPases with or without ligand. The distances from ADP to the His20 in the 
His-Ser-His motif and the Arg finger (Arg353 or Arg378) in both RUVBL1/2 complex structures 
bound with or without ADP have significant differences, suggesting dramatically different 
interactions of the binding site with ADP. Taken together, the inhibitors of six well-studied AAA 
ATPases and their structural information suggest further development of specific AAA ATPase 
inhibitors due to difference in their structures. Future chemical biology coupled with proteomic 
approaches could be employed to develop variant specific, complex specific, and pathway 
specific inhibitors or activators for AAA ATPase proteins. 
Keywords: AAA ATPases; Small molecule inhibitors; p97; RUVBL1/2; ATAD2 
1. Introduction 
ATPases Associated with Diverse Cellular Activities (AAA ATPase proteins) are a kind 
of enzymes sharing a common conserved ATP-binding domain of approximately 200 to 250 
amino acid residues and oligomerizes into hexamers.  These ATPases belong to a functionally 
diverse protein family of the AAA protein superfamily of ring-shaped P-loop NTPases that 
catalyze the hydrolysis of a phosphate bond in adenosine triphosphate (ATP) to form adenosine 
diphosphate (ADP) and release inorganic phosphate. Th y provide energy to facilitate a variety 
of cellular processes that are essential for life: ncluding protein folding [1], intracellular 
transport [2], protein degradation [3], initiation f DNA replication [4], DNA repair [5], DNA 
remodeling [6], and ion transport [7]. To date, there are 53 members in the AAA ATPase family 
based on the HGNC database [8], some of which have been characterized and identified as 
druggable targets to explore as potential treatments for some diseases such as cancer [9-11] and 
Alzheimer’s disease [12, 13]. Most AAA ATPases form barrel-shaped hexameric rings, where 
each monomer consists of one or two ATPase domains ( lso known as D1 and D2) together with 
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a regulatory N-terminal domain. Each ATPase domain co tains a conserved Walker A domain, 
Arginine finger, and Walker B domain.  
Recent reviews have summarized AAA ATPase inhibitors for p97 (14,15), ATAD2 
(16,17), and dynein (18,19). Wipf and co-authors reviewed the discovery, optimization, 
characterization, and therapeutic potential of p97 inhibitors, which were classified into D2 ATP 
Site Inhibitors, D1-D2 Linker region allosteric Inhibitors, covalent inhibitors, and inhibitors with 
unknown mechanisms of action [14]. Sui and co-authors reviewed molecular mechanism, 
cofactors, and small-molecule inhibitors of p97 [15]. Hussain and co-authors reviewed the 
functions of ATAD2 in normal physiology and cancer-etiology and discussed technical 
challenges rendered by ATAD2’s BRD active site and the drug discovery efforts to find small 
molecule inhibitors against ATAD2 [16]. Due to the specificity of ATAD2 structure, Magnuson 
et al. briefly reviewed ATAD2 inhibitors in the summarization of Bromodomain inhibitors [17]. 
Steinman et al. discussed the cellular functions and conformationl dynamics of AAA ATPase 
(including p97, dynein, and midasin) inhibitors [18]. Additionally, Shimizu summarized a few 
dynein inhibitors [19]. In summary, all these reviews mainly focus on small-molecule inhibitors 
against p97, ATAD2, or dynein. In this review, we discussed and analyzed the three-dimension 
structures of the well-studied p97, RuvBL1/2, ATAD2, and spastin as well as small molecules 
inhibitors because structural information for inhibitor binding pocket are available. We also 
picked two additional AAA ATPases, midasin and dynein, because they are potential drug 
targets. Due to the complicated structural arrangement of six not identical AAA domains in a 
single polypeptide for midasin and dynein, the inhibitor developments are mainly based on cell-
based screenings and future works are needed to identify binding sites of inhibitors of midasin 
and dynein. We proposed the binding mode for some representative inhibitors by docking studies  
in this review. Because the p97 inhibitors have been summarized by several reviews, herein we 
only include some p97 inhibitors.  
2. Selected AAA ATPases 
2.1 p97/VCP/Cdc48/TER ATPase 
p97, also known as the Valosin-containing Protein (VCP), is a homolog of the cell 
division cycle protein 48 (Cdc48) in Saccharomyces cerevisiae, and of translational ER ATPase 
in Drosophila. In 1982, Moir and co-authors identified Cdc48 as one of the 18 cold-sensitive 
cell-division-cycle (cdc) mutants in Saccharomyces cerevisiae [20]. Five years later, Koller and 
co-authors identified a supposed valosin-co taining protein and concluded that valosin is an 
artifact during purification [21]. Since then, the name VCP has be used widely. In 1990, Peters 
and co-authors discovered a 97 kDa protein from Xenopuslaevis oocytes and mapped its amino 
acids to VCP [22].  In 1996,  Ghislain and co-authors identified that Cdc48 is required for 
degrading the ubiquitin-fusion-degradation substrates, which is the first reported link of Cdc48 to 
the protein degradation pathway [23].  
p97/VCP is highly conserved and involved in many biological processes, including 
endoplasmic reticulum-associated degradation (ERAD), Golgi reassembly, transcription 
regulation, and cell cycle control [24]. p97 is mainly localized in the cytosol and also present on 
organelle membranes including the endoplasmic reticulum (ER), Golgi, mitochondria, and 
endosomes [25-29]. p97 is composed of a substrate and cofactor binding N domain followed by 
two AAA ATPase domains termed D1 and D2, C-terminal and could form a hexameric double-










and ATP concentration, whereas D1 is involved in the regulation of heat-induced ATPase 
activity [32] and hexamerization [33, 34]. The D1 domain binds to ATP/ADP tighter than the D2 
domain and has 10-fold higher catalytic efficiency via reduction in Km [35]. There are conserved 
arginine finger, walker A (GPPGCGKT), and walker B (VLFFDELD) in each domain 1 and 2. 
The structures of p97 with truncated or full-length sequences have been resolved using x-ray 
diffraction, electron microscopy, and solution NMR (Table 1).  
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Figure 1. (A) Schematic diagram of the p97 domain organization. (B) Top view of the 
crystal structure of p97 (PDB code 5FTK). (C) Side view of p97. N domain, D1, D2, and C-
terminal are presented in magenta, yellow, cyan, and green, respectively.  
A B C 
Figure 2. (A) Full-length p97 (5FTK and 3CF2). For 5FTK, N domain, ND1 linker, D1, 
D1D2 linker, and D2 are presented in magenta, gray, yellow, green, and cyan, respectively. 
For 3CF2, N domain, ND1 linker, D1, D1D2 linker and D2 are presented in pink, gray, 
limon, smudge, and deepteal, respectively. (B) The binding site of ADP in Domain 2 (5FTK 
and 3CF0). 5TFK-ADP and 3CF0-ADP are in black and orange, respectively. The Walker A 
and B are presented as cartoons, and the carbons of 5FTK and 3CF0 are shown in green and 
cyan, respectively; (C) The Walker A, Walker B and Arginine Finger 635 (5FTK and 3CF0). 
5ftk-walker A, 5ftk-walker B, 5ftk-Arg Finger, 3cf2-walker A, 3cf2-walker B, and 3cf2-Arg 
Finger are presented in magenta, yellow, cyan, hotpink, limon, and deepteal, respectively. 










Table 1. Crystal Structures of p97 
PDB 
Code 
Methods (Å) P97 Domains Ligands Organisms References 
1E32 X-ray (2.9) 
N-D1:N21-Q458 
(sequence:M1-G481) 
ADP in D1 mmu [36] 
1R7R X-ray (3.6) 
N-D1-D2-C: L17-K336, A339-D609, N616-S664,D669-
S702,P727-H735 
(sequence: M1-G806+AALEHHHHHH) 
ADP in D1 mmu [37] 
1S3S X-ray (2.9) 
N-D1:K18-Q458 
(sequence: M1-Q458) 
- mmu [38] 
3CF0 X-ray (3.0) D2#:A463-I707, V728-Q763(sequence: A463-Q763) ADP mmu [39] 
3CF1 X-ray (4.4) N-D1-D2-C#: N21-I707, V728-Q763 (sequence: M1-G806) 
ADP in D1 and D2 
AF3 in D2 
mmu 
[39] 
3CF2 X-ray (3.5) 
N-D1-D2-C#: N21-I582, A597-A622, N624-I645, K651-S664, 
A667-D669, D686-E704, V728-E730, H735-M740, E756-A759 
(sequence: M1-G806) 




3CF3 X-ray (4.3) N-D1-D2-C#: N21-I707, V728-Q763(sequence: M1-G806) ADP mmu [39] 
4KOD X-ray (3.0) R155H N-D1*: K18-S462 (sequence: M1-G481+RSHHHHHH) ADP in D1 hsa [40] 
5C1B X-ray (3.1) 
N-D1-D2-C: N21-G587, G594-R708, P729-S770 (sequence: A2-
R708; P729-G806) 
AGS in D1 and D2 hsa [41] 
5C18 X-ray (3.3) 
N-D1-D2-C: K20-G588, A596-R708, P729-G769 (sequence: A2-
R708; P729-G806) 
AGS in D1 and D2 hsa [42] 
5DYI X-ray (3.7) N-D1*: N21-P461 (sequence: M1-G481+RSHHHHHH) ADP in D1 hsa [43] 
5FTJ EM (2.3) N-D1-D2-C: N21-I707, V728-Q763 (sequenc : M1-G806) 
ADP in D1 and D2, 
UPCDC30245 in 
the junction of D1 
and D2 
hsa [44] 
5FTK EM (2.4) N-D1-D2-C: N21, V728-Q763 (sequence: M1-G806) ADP in D1 and D2 hsa [44] 
5FTL EM (3.3) N-D1-D2-C: N21-I707, V728-Q763 (sequence: M1-G806) ADP in D1 and D2 hsa [44] 
5FTM EM (3.2) N-D1-D2-C: N21-I707, V728-F768 (sequenc : M1-G806) 
ADP in D1, AGS in 
D2 
hsa [44] 
5FTN EM (3.3) N-D1-D2-C: L12-I707, V728-F768 (sequence: M1-G806) AGS in D1 and D2 hsa [44] 
6CHS EM (4.3) 
P97-Npl4 complex N-D1-D2 N215-E725, P745-A783 (sequence: 
M1-T819) 
AGS in D1 and D2 cthr [45] 
6G2V X-ray (1.9) 
D2: V468-T549, S555-K584, A596-E712, V728-Q764 
(sequence: GPG+S462-T549; S555-A585; A597-E712; V728-











6G2W X-ray (2.7) 
D2: V468-T549, S555-K584, A596-E712, P727-Q763 (sequence: 
GPG+S462-Q764) 
ADP hsa [46] 
6G2X X-ray (2.1) 
D2: V468-T549, S555-K584, A596-E712, P727-Q764 (sequence: 
GPG+S462-Q764) 
ADP hsa [46] 
6G2Y X-ray (2.2) 
D2: V468-T549, S555-K584, A596-E712, P727-Q763 (sequence: 
S462-Q764) 
ADP hsa [46] 
6G2Z X-ray (1.9) 
D2: V468-T549, S555-K584, A596-E712, P727-Q763 (sequence: 
GPG+S462-Q764) 
ADP hsa [46] 
6G30 X-ray (2.4) 
D2: V468-T549, S555-K584, A596-E712, P727-Q763 (sequence: 
GPG+S462-Q764) 
ADP hsa [46] 
6MCK X-ray (3.8) 
D1-D2*: R210-R424, V447-R586, A596-T715, E730-Q763 
(sequence: M+R210-G806+RSHHHHHH) 
CB5083 in D2 hsa [47] 
* Dodecamer; # heptamer; - no ligands. 
Hsa, cthr, and mmu stand for Homo sapiens, Chaetomium thermophilum, and Mus musculus, respectively. 
Human and mouse p97 amino acid sequences are identical.  










It is known that p97 was upregulated in many cancer types and associated with poor 
prognosis in some cancers [48, 49] and involved in neurodegenerative diseases [50]. The 
downregulation of p97 with siRNAs could cause endoplasmic reticulum (ER) stress and activate 
apoptosis through the unfolded protein response (UPR), a pathway that acts both to resolve 
unfolded protein stress and to trigger cell death when the buildup of such unfolded proteins 
becomes irresolvable [51, 52]. In addition, the downregulation of p97 could also dramatically 
suppress the genesis and progression of tumors in vivo [53]. Therefore, p97 has been pursued as 
a cancer drug target. Currently, there are many p97inhibitors reported, including ATP 
competitive, uncompetitive, and non-competitive inhibitors, some of which are reversible 
inhibitors and others are irreversible inhibitors. Here we describe the main inhibitors of p97. 
Dibenzylquinazolines 
N2, N4-dibenzylquinazoline-2,4-diamine (DBeQ, 1) is a reversible, ATP-competitive p97 
inhibitor with IC50 of <10 µM in the ATPase activity assay [54, 55]. DBeQ also showed 50-fold 
selectivity over other unrelated ATPase activities, including the N-ethylmaleimide-sensitive 
factor (NSF) and the ATP-dependent chymotryptic activity of the 26S proteasome. DBeQ 
upregulated C/EBP-homologous protein (CHOP) resulted in cell death, suggesting that DBeQ-
dependent inhibition of p97 resulted in a lethal ER stress response. DBeQ also enhanced 
lipidation of the microtubule-associated protein light chain (LC3 or LC3-B), which indicated that 
DBeQ induced autophagy [54, 56]. Inspired by DBeQ, the structure-activity relationship (SAR) 
studies that were performed on the dibenzylquinazoline analogs led to the discovery of two 
compounds, ML240 (2) and ML241 (3), with different substitutions at the N2 position  
quinazoline scaffolds. Both ML240 and ML241 were ATP-competitive p97 inhibitors and 










showed similar in vitro ATPase activity. However, they showed mechanistically different modes 
of action [56, 57]. ML240 induced the accumulation of LC3-B and was more potent than ML241 
in the antiproliferative effects assessed in the NCI-60 cancer cell line panel.  
CB-5083 (4), the first p97 inhibitor enter clinical trials in the US is analog of the 
dibenzylquinazoline, was developed as a D2 domain selective, first-in-class p97 inhibitor with an 
IC50 of 11 nM [58, 59]. The crystal structure CB-5083 showed  it competes with ATP to bind at 
the binding site in Domain 2 [53] (PDB Code 6MCK, Figure 4A), which was consistent with 
DBeQ, ML240, and ML241. All the dibenzylquinazolines share the same binding site. CB-5083 
affected the expression of mediators of the UPR [9] and significantly altered  genes, including 
CHOP, DR5, HSPA5, HERPUD1, SEL1L, SYVN1 and EDEM1. CB-5083 showed promising 
antitumor responses in colorectal cancer, lung cancer, plasmacytoma tumor xenografts, and 
patient-derived xenograft models of colorectal cancer [9]. Despite its promising anti-cancer 
activity, CB-5083 failed its Phase I clinical trials against relapsed/refractory multiple myeloma 
and advanced solid tumors, due to an inhibition of PDE6 that caused blindness. This side effect 
was investigated in studies on gene expression and cell viability [9]. In 2019, LC-1028 (5) was 
developed by introducing a Michael acceptor to replace the amido group in CB-5083. LC-1028 
showed promising potency, with Ki
app = 33.2 ± 4.0 nM and EC50 = 436 nM in antiproliferative 
assays (MIA PaCa-2 cells) [60]. The docking study indicated that the Cys522 thiol in the active 
site of p97 is indeed poised for a nucleophilic attack onto the electrophilic ynamide moiety of 
LC-1028. MS/MS studies supported covalent modification of Cys522. Interestingly, LC-MS/MS 
analysis of p97 incubated with LC-1028 has also identifi d Cys105 as an off-target labelling site, 
which was further evidenced by slow adduct formation (t1/2 = 16.4 h) with intracellular GSH [60].  
Alkylsulfanyl-1,2,3-triazoles  
NMS-873 (6), is an allosteric p97 inhibitor, which induces the accumulation of 
polyubiquitinated proteins, leading to ER stress and inhibition of autophagosome maturation [61, 
62]. NMS-873 is thought to bind to the linker domain between the D1 and D2 ATPase domains 
of p97, which stabilizes D2-ADP bound p97 [63]. We performed docking study to investigate the 
binding mode of NMS-873, which was proposed in F gure 4B [64]. Bastola et al. validated the 
binding site of NMS-873 by the mutations at nearby residues, which abrogated or significantly 
reduced the activity of NMS-873 [65]. NMS-873 showed potent inhibition against cell 
proliferation on HCT116 cells with IC50 of 400 nM [66]. Cellular assays indicated a dose-
dependent accumulation of ubiquitinated proteins, activ tion of the unfolded protein response, as 
well as stabilization of key proteins (such as Mcl-1, cyclin E) at concentrations with 
demonstrated antiproliferative activity. Compared to the approved proteasome inhibitor 
bortezomib, NMS-873 showed a distinct profile with broader effects in tumor cell line panels. 
We have shown that allosteric p97 inhibitors can inhibit CB-5083 resistant p97 both with 
purified mutants and cell lines [67].  
Despite the notable in vitro activity, NMS-873 showed poor bioavailability (around 16%), 
modest solubility (7 µM), and high clearance (based on in vitro microsomal data) [66]. 
Additionally, NMS-873 exhibited antiviral properties by inhibiting the production of the 
infectious virus in primary human fibroblast cells (targeting p97), with IC50 of 0.13 µM (the 
clinically used ganciclovir IC50 = 1.3 µM) [68]. NMS-873 was also reported to be effective 
against influenza and prevented viral replication in H1N1 strains, as well as in drug-resistant 
strains, with EC50 and selectivity indices ranging from 30-55 nM and 50-100 (CC50/EC50), 










(8, IC50=7 nM) demonstrate significant biochemical potencies [70, 71]. Both the ATP-
competitive inhibitors (DBeQ, ML240 and ML241) as well as the allosteric inhibitor NMS-873 
have differential effects on the D1 and D2 ATPase activity of p97. DBeQ and NMS-873 inhibit 
ATPase activity from both the D1 and D2 domains, while ML240 and ML241 seem to inhibit 
selectively the D2 domain of p97 [35]. 
Tetrahydrocarbazoles 
MSC1094308 (9, Figure 5A) was identified as an allosteric p97 inhibitor and exhibited 
moderate biochemical potency (IC50 = 7.2 µM) in the high-throughput screening campaign in 
2018 [72]. Kinetic analysis of the interaction betwen p97 and MSC1094308 showed non-
competitive inhibition. Structure-activity relationship analysis showed the changes to the 
carbazole system, and the diphenyl-methane moiety didn’t improve the potency significantly. 
Additionally, MSC1094308 is also a VPS4B inhibitor with an IC50 value of 0.71 µM. Although 
VPS4B affinity over p97 could be increased up to 40-fold in this series, no p97-selective 
compounds were discovered. The binding pocket for MSC1094308 series was further validated 
by exposing p97 to a MSC1094308-based photoaffinity probe which cross-linked residues at the 
same site occupied by UPCDC30245 and NMS-873 (Figure 5B). The reduced potency of 
MSC1094308 against the N616F p97 mutant showed a common allosteric binding site for these 
three different scaffolds, which is considered a sensor for the NMS-873 allosteric binding site. 
Despite its low biochemical potency, MSC1094308 waseffective in cellular assays when dosed 
at 10 µM and caused the accumulation of ubiquitinated substrates, as measured by Western blot. 
NMS-859 
NMS-859 (10, Figure 5A), sharing an α-chloroacetamide, is a highly potent p97 inhibitor. 
The enzymatic inhibition by NMS-859 is time-dependet and covalent, which is validated by the 
mass spectrum of p97 incubated with NMS-859 [61]. Compared to the nonspecific agents, such 
as N-ethylmaleimide targeting 6-8 cysteine residues of p97, NMS-859 bonded covalently at 
Cys522, which is proximal to the key residue Lys524 at D2 domain catalytic site. In order to 
investigate the binding mode, we performed a covalent docking study for NMS-859 to p97 (5FTJ) 
(Figure 5C). In addition to the covalent bond with C522, some significant interactions were 
proposed, such as the hydrophobic interaction from L526, the hydrogen interaction from T688, 
and the carbonyl-πinteraction from N660. NMS-859 induced protein dysregulation and wild 
type Hela cell death with an IC50 of 3 µM. The p97-C522T mutant showed resistance to NMS-
Figure 4. CB-5083 (PDB: 6MCK, A) and NMS-873 (proposed binding mode, PDB: 6MCK, 
B) in binding sites of p97 with a vacuum electrostatic surface. The D1, D1D2 linker, and D2 











859-mediated inhibition. This effect was also recapitulated at the cellular level where NMS-859 
showed a 3-fold increase in IC50 and no downstream effects on Hela cells expressing the mutant 
protein. As expected, NMS-859 was inactive against a panel of other AAA ATPases. The 
binding pocket of NMS-859 was defined using the keyr sidues Leu526, Asn660, and Thr688 
identified by computational studies [73]. Due to the selectivity, NMS-859 could be a promising 
starting point to design the covalent p97 inhibitors. 
Pyrazolo[3,4-d]pyrimidines 
Recently, a series of pyrazolo[3,4-d]pyrimidine analogs were reported to show p97 
inhibition activity [74]. A covalent inhibitor, PPA (11, Figure 5D) from this series, exhibited at 
least 450-fold and 150-fold selectivity against wild type p97 over the yeast Cdc48 and the N-


































Figure 5. Chemical structure (A) and the proposed binding mode of MSC1094308 (9, PDB 
code 5FTJ, B), NMS-859 (10, PDB code 5FTJ, C), PPA (11, PDB code 5FTK, D) and 
curvularin (12, PDB code 5FTJ, E) with p97. The N, ND1 linker, D1, D1D2 linker, and D2 










by tandem mass spectrometry, verifying that PPA covalently bound with Cys522. PPA could 
effectively inhibit the proliferation of HCT116, HeLa, and RPMI8226 with IC50 values of 2.7 
µM, 6.1 µM, and 3.4 µM. Additionally, PPA showed inhibition on CB-5083-resistant and NMS-
873-resistant HCT116 cell lines. Therefore, PPA could serve as a lead compound to further 
structural optimization. 
Curvularins 
The dehydrocurvularin (DHC) and its chlorinated variants were identified as covalent 
p97 inhibitors by interfering with its ATPase activity, which are members of the macrocyclic 
lactone family of curvularins produced by several fungal species [75]. The dehydrocurvularin 
inhibited p97 by covalently bonding to Cys522 (12, Figure 5E) in a dose-dependent manner 
with an IC50 of 15.3 ± 9.9 µM, which caused the p97-dependent accumulation of 
polyubiqutinated substrates in cellular assay. The c lorinated variant 4,6-chlorinated derivative 
was more selective against p97-dependent ERAD than general proteasomal effects.    
 2.2 RUVBLs 
RUVBL1 (TIP49, TIP49a, Rvb1, Pontin) and RUVBL2 (TIP48, TIP49b, Rvb2, Reptin) 
are highly conserved AAA ATPases which are involved in various cellular processes. Originally, 
RUVBL proteins were isolated from Escherichia coli and were designated as RuvA and RuvB 
[3]. Later, the homologues of RUVBL1 and RUVBL2 in humans, rats, and yeast (TIP49/TIP49a 
and TIP49b/TIP48) were characterized to interact with TATA-box binding protein (TBP) [76-
A 
B C 
Figure 6. (A) Schematic diagram of the RUVBL1 and RUVBL2 domain organization. (B) 
Top view of the crystal structure of RUVBL1/2 complex (PDB code 5OAF). (C) Side view of 
RUVBL1/2 complex. For RUVBL1, D1, D2 and D3 are presented as a cartoon in yellow, 
cyan, and magenta; For RUVBL2, D1, D2 and D3 are presented as cartoons in limon, teal, 










Table 2. Crystal Structures of RUVBL1, RUVBL2 and RUVBL1/2 complex 
PDB 
Code 
Methods (Å) Macromolecules Ligands Organisms References 
2C9O X-ray (2.2) RUVBL1: K9-C141, H156-N247, G277-D449 (Sequence: M1-K456) ADP hsa [80] 
2CQA NMR (NA) 
RUVBL2 C-terminal: GSSGSSG+K132-R213+SGPSSG (Sequence: 
GSSGSSG+K132-R213+SGPSSG) 
- hsa - 
2XSZ X-ray (3.0) 
RUVBL1 ∆DII: E5-R123, I235-R249, T269-K453 (Sequence: 
MVHHHHHHLLVPRGS+K2-E126+GPPG+I234-K456)/RUVBL2 ∆DII: I22-
I131, H240-T254, E267-K456 (Sequence: MDYKDDDDKENLYFQG+A2-
E133+GPPG+V238-S463) 
ATP hsa [81] 
3UK6* X-ray (3.0) 
RUVBL2 ∆DII: T8-E12, D15-I131, T241-F261, E267-K444 (Sequence: M1-
K132+AGA+V239-S463+LEHHHHHH) 
ADP hsa [82] 
4WVY* X-ray (3.6) 
RUVBL1: I4-E142, T157-P251, I257-T449 (Sequence: M1-S462)/RUVBL2: 
H26-I145, Q157-A209,F223-D457 (Sequence: 
MGSSHHHHHHHHSSGLEVLFQGPGS+M1-S488) 
ATP cthr [83] 
4WW4* X-ray (2.9) 
RUVBL1: Q3-V136, S156-K169, L173-D174, Q182-C201,R206-P251, D256-
T451, G455-H458 (Sequence: M1-S462)/RUVBL2: T7-R149, G153-R212, 
F223-G229, Q232-V456 (Sequence: 
MGSSHHHHHHHHSSGLEVLFQGPGS+M1-S488) 
ADP cthr [83] 
5FM6* X-ray (3.0) 
RUVBL1: Q3-T140, T157-T198, G205-S450 (Sequence: GA+M1-
S462)/RUVBL2: S8-E14, H26-R149, G158-R210, T221-V455 (Sequence: 
GA+M1-S488) 
ADP cthr [84] 
5FM7* X-ray (2.9) 
RUVBL1: Q3-E138, I160-T198, G205-P251, Q255-S450 (Sequence: GA+M1-
S462)/RUVBL2: S8-L15, I21-R149, K159-A209, K222-V455 (Sequence: 
GA+M1-S488) 
ADP cthr [84] 
5OAF EM (4.1) 
INO80 complex RUVBL1: K11-D452 (Sequence: M1-K456)/RUVBL2: V16-
R211, P228-A449 (Sequence: M1-S463) 
ADP hsa [85] 
5OUN NMR (NA) RUVBL2 DII: GPHM+E132-T234 (Sequence: E132-T234) - sce [86] 
6FHS EM (3.8) 
INO80 complex RUVBL1: I4-S462 (Sequence: M1-S462)/RUVBL2: L20-
F458 (Sequence: M1-S488) 
ADP cthr [87] 
6FML EM (4.3) 
INO80 complex RUVBL1: I4-S462 (Sequence: M1-S462)/RUVBL2: L20-
F458 (Sequence: M1-S488) 
ADP cthr [87] 
6FO1 EM (3.6) 
R2TP Subcomplex RUVBL1: E5-I124, I235-R249, T269-K456 (Sequence: 
M1-K456)/RUVBL2: I22-I131, H240-R253, E267-N453 (Sequence: M1-
S463) 










6GEJ EM (3.6) 
Nucleosome complex RUVBL1: V21-L463 (Sequence: M1-L463)/RUVBL2: 
L14-K460 (Sequence: M1-E471) 
ADP sce [89] 
6GEN EM (3.6) 
Nucleosome complex RUVBL1: V21-L463 (Sequence: M1-L463)/RUVBL2: 
L14-K460 (Sequence: M1-E471) 
ADP sce [89] 
6H7X X-ray (2.9) 
RUVBL2: S43-I147, K160-K184, Q188-I202, P228-S252, G256-K456 
(Sequence: M1-S463) 
- hsa [90] 
6HTS EM (4.8) 
INO80 Complex RUVBL1: T12-Y454 (Sequence: M1-K456)/RUVBL2: D15-
P150, S156-N453 (Sequence: M1-S463) 
ADP hsa [91] 
6IGM EM (4.0) 
SRCAP Complex RUVBL1: Q13-E142, I154-P250, T269-I446 (Sequence: 
M1-K456)/RUVBL2: V16-P150, K157-T183, D191-I202, Q226-A449 
(Sequence: M1-S463) 
- hsa [92] 
6K0R* X-ray (2.5) 
RUVBL1 ∆DII: E5-I124, I235-R249, T269-Q451 (Sequence: GPS+K2-
E126+GPPG+ I234-K456)/RUVBL2 ∆DII: H25-I131, H240-N251, E267-






6QI8 EM (3.8) 
RUVBL1: K2-I120, D237-R249, T272-K456 (Sequence: M1-K456)/RUVBL2: 
T8-I131, S243-N453 (Sequence: M1-S463) 
ADP hsa [94] 
6QI9 EM (4.6) 
RUVBL1: K2-I120, D237-R249, T272-K456 (Sequence: M1-K456)/RUVBL2: 
T8-I131, S243-N453 (Sequence: M1-S463) 
ADP# hsa [94] 
Hsa, cthr, and sce stand for Homo sapiens, Chaetomium thermophilum, and Saccharomyces cerevisiae, respectively. 
* The complex was assembled as Dodecamer; # The hexameric RUVBL1/2 complex only binds with 5 ADP molecules. 
NA: not applicable. 










They share the conserved motifs Walker A and Walker B, which have been characterized to bind 
and hydrolyze ATP [95]. RUVBL1 and RUVBL2 share 43% sequence identity and 65% 
sequence similarity and work together as part of chromatin remodeling complexes [96-100]. 
Although RUVBL1 and RUVBL2 are present in the cytoplasm and associated with the cell 
membranes, they are mainly localized in the nucleus and associated with the nuclear matrix or in 
the nuclear cytosol. 
Both RUVBL1 and RUVBL2 contain N-terminal, Domain 1, Domain 2, Domain 3, and 
C-terminal. Together with the internal region of Domain 2, the Domains 1 (the typical Rossman-
like αβα fold) and 3 (the canonical all-α subdomain) provide typical oligomeric rings of an AAA 
core, which is formed by a conserved Walker A motif (required for nucleotide binding), a 
conserved Walker B motif (required for ATP hydrolysis). Domain 2 of RUVBLs contains two 
sub-domains, including an oligonucleotide-binding fold (external D2 or D2 ext or α/β Tip) and a 
base region closer to the AAA ring (internal D2). The D2 domain was involved in several 
protein–protein interactions as observed in the INO80 complex [101], the yeast SWR1 complex 
[102], the PAQosome [103], and the R2TP complex [104]. The conserved motif HSH in 
RUVBL2 is responsible for the nucleotide binding but not hydrolysis [81,83,87,89,91]. Although 
RUVBL1 and RUVBL2 share homology with the bacterial RuvB helicase [3, 105, 106], their 
functions as helicases are not yet established and remain controversial. It is observed that their 
oligomeric states were shown as homo-hexamers, hetero-hexamers, and even hetero-dodecamers 
[80,81,107,108]. Although the heptamer of the RUVBL1/2 complex could be observed in a 
preliminary negative staining EM analysis [90], no available heptameric structure was reported. 
The different oligomeric states were dependent on different functional contexts based on their 
cellular activities [99, 109].  
There is an increasing number of structures of RUVBL proteins reported, which were 
resolved by x-ray diffraction, electron microscopy, or solution NMR (Table 2). In order to better 
understand the structure of the RUVBL1/2 complex, we employed molecular modeling to 
overlay the RUVBL1/2 complex bound with ADP (5OAF) and without ligands (6IGM) 
(RMSD=1.315). The external Domain 2 of the RUVBL1/2 complex without ADP showed 
significant disordered compared to the structure of RUVBL1/2 complex with ADP. Due to the 
RMSD between 5OAF and 6IGM, we used ADP in 5OAF as the reference during the structural 
comparison. Some residues in the binding site showed significant shift, such as His20 in the 
HSH motif, the Arg finger 353, and Arg378 (Figure 7 and Table 3), which greatly decreased the 
interaction with ADP. Some mutations, such as RUVBL1 E303Q and RUVBL2 E300Q, led to 
the loss of activity. The complex formed by W-T RUVBL1/RUVBL2 E300Q or RUVBL1 
E303Q/W-T RUVBL2 showed lower ATPase activity by 2.5-fold and 6.4-fold decrease 
compared to W-T RUVBL1/W-T RUVBL2, which indicated that both RUVBL1 and RUVBL2 
contribute to the ATPase activity [10]. The RUVBL1 and RUVBL2 are involved in many 
cellular activities— including transcriptional regulation, chromatin remodeling, DNA damage 
signaling and repair, assembly of macromolecular complexes, regulating cell cycle/mitotic 
progression, and cellular motility— all of which contribute to their central roles in promoting 
cell proliferation and survival [99, 110-114]. RUVBL1 and RUVBL2 were shown to be essential 
for tumor cell growth of many cancers [79, 115] and were found to be overexpressed in many 










Table 3 Distance between ADP and the residues at the binding site of 5OAF (with ADP) and 







His20-A NH 16 2.5 5.0 
Val40-A 
NH 1 2.8 3.1 
NH 10 3.0 3.3 
C=O 10 3.0 3.2 
Gly73-A NH 26 3.0 2.7 
Thr77-A NH 27 2.9 3.1 
Arg378-A 
NH2 16 2.6 4.2 
NH2 17 2.5 3.9 
Arg404-A NH 19 2.5 2.8 
Glu317-B C=O 25 2.9 2.5 
Arg353-B 
NH 23 2.8 2.6 
NH2 23 2.9 4.9 
Elkaim et al. identified the first small-molecule inhibitors ofRUVBL1 by employing 
virtual screening and enzymatic assay [116]. Three compounds 13, 14, and 15 with IC50 values in 
Figure 7. Overlay of RUVBL1/2 complex with (5OAF) or without (6IGM) ADP. (A) 
Overlay of full-length RUVBL1/2 complex, RUVBL1/2 complex with ADP (5OAF) is in 
green (ADP in red), RUVBL1/2 complex without ADP (6IGM) is in cyan. (B) Overlay of the 
binding site of ADP. ADP is in yellow. The interacted residues are presented as lines. The 











HuH7 and Hep3B cells of 0.57 and 0.25 µM for Rottlerin, 4.0 and 3.5 µM for Akt1/2 inhibitor, 
and 63.7 and 34.3 µM for Pranlukast tested reduced cell growth at concentrations close to those 
inhibiting the ATPase activity of RUVBL1 in vitro. However, their anti-proliferative action 
would require further study. Encouraged by the promising results of the first small-molecule 
inhibitors of RUVBL1, Elkaim et al. performed another virtual screening to hunt for RUVBL1 
inhibitors, which led to the identification of two original scaffolds [117]. Two compounds 16 and 
17 showed RUVBL1 inhibition in ATP-dependent mode with an IC50 at 9 and 18 µM, 
respectively. Compound 16 demonstrated the antiproliferative activity with the IC50s for KB and 
HL60 cells of 9 and 15 µM, which induced apoptotic cell death together with necrosis. 
Compound 18 was initially identified as the RUVBL1/2 complex inhibitor by screening 
and structural optimization of the hits from a custom library [118] that has a half maximal 
inhibitory concentration of 59 nM against RUVBL1/2. By inhibition of RUVBL1/2 in cells, 
compound 18 depleted PIKK-family members DNA-PKcs (PRKDC), ATM, and ATP, all of 
which require RUVBL1/2 ATPase activity for stability [119]. In mice bearing subcutaneous 
NSCLC xenografts, compound 18 inhibited RUVBL1/2 and reduced the levels of ATM, ATR, 
and DNA-PKcs [103]. Compound 18 could arrest NSCLC cells in S phase, which eventually 
culminated in apoptosis indicated by the sub-G1 population in DNA content analysis. However, 
compound 18 in NSCLC in vivo exhibited a modest therapeutic window. 
CB-6644 (19 in Figure 8), an allosteric small-molecule inhibitor of the RUVBL1/2 
complex, showed potent inhibition against p97 with an IC50 of 15 nM in an ATP-dependent 
manner, which interacts specifically with RUVBL1/2 in cancer cells, leading to cell death [10]. 
In a panel of 123 cancer cell lines, CB-6644 potently killed cells with an EC50 range of 41 to 785 
nM. Despite the maximal inhibition of around 50% in the biochemical ATPase assay, more than 
95% of cells from all the cell lines were killed at the concentration range of 81 nM to 6.59 µM. 
CB-6644 demonstrated potent inhibition against tumor growth without obvious toxicity in 
xenograft models of Burkitt lymphoma and multiple myeloma. Although CB-6644 showed 
promising activity as RUVBL1/2 inhibitor, the binding site on RUVBL1/2 remains to be 
clarified. 
2.3 ATAD2 










ATPase family AAA domain-containing 2 (ATAD2) is a chromatin regulator harboring 
an AAA ATPase domain and a bromodomain and has beenidentified as a critical modulator 
involved in cell proliferation and invasion. ATAD2 is co-expressed with genes involved in DNA 
replication in various cancer types and predominantly expressed in S phase cells where it 
localized on nascent chromatin (replication sites). Overexpression of ATAD2 has been linked to 
poor prognosis in prostate, lung, and triple-negative breast cancers, as well as in hepatocellular 
carcinoma [11, 120-122]. Downregulation of ATAD2 via siRNA shows an increase in apoptotic 
activity [11]. ATAD2 is recruited to replication sites through a direct interaction with di-
acetylated histone H4 at K5 and K12, indicative of newly synthesized histones during 
replication-coupled chromatin reassembly [123]. Drug discovery efforts for oncology so far have 
focused on the ATAD2 bromodomain rather than its ATPase domain due to the tractability of 
most screening approaches [16]. Herein we summarized all the available crystal structures of 
ATAD2 (Table 4), which mainly focus on ATAD2 bromodomain. 
Several studies were performed on the discovery of ATAD2 inhibitors. Harner et al. 
identified some hits against ATAD2 using NMR spectroscopy by a fragment-based approach 
[124]. These hits bound the bromodomain of ATAD2 with Kd values of 600, 350 and 500 µM. 
The co-crystals of ATAD2 suggested that these three its occupied the same general space with 
the Kac binding pocket. There is still ample opportunity to optimize these structures and improve 
drug-like properties.  
Demont et al. identified two ATAD2 bromodomain inhibitors by fragment-based 
discovery, with the same pIC50 of 5.9 against ATAD2 [125]. Due to the selectivity, compound 20 
was used as the lead compound to further optimize the structure and improve the potency as well 
as selectivity. The introduction of the thiopyran ri g on 3’-position led to compound 21, which 
showed pIC50 of 6.9 and >100-fold selectivity over the BET bromodomains [126]. However, 
some disadvantages, such as greater hydrophilicity and the passive permeability, limited further 
development. The methylated 21 on the piperidyl ring, compound 22, mitigated these 
disadvantages with some off-target activity against other bromodomains. In order to improve cell 
permeability and selectivity over the BET bromodomains, the structure of naphthyridones was 
optimized by replacing SO2 with the polar hydrophobic isostere CF2 [127].  










Table 4. The structures of ATAD2 
PDB 
Code 
Methods (Å) Macromolecules Ligands Organisms References 
3DAI X-ray (2.0) SM+Q981-R1108 - hsa [128] 
4QSP X-ray (1.6) SM+Q981-R1108 N(6)-ACETYLLYSINE hsa [129] 
4QSQ X-ray (1.8) SM+Q981-R1108 - hsa [129] 
4QSR X-ray (2.0) SM+Q981-R1108 - hsa [129] 
4QSS X-ray (2.0) SM+Q981-R1108 - hsa [129] 
4QST X-ray (2.1) SM+Q981-R1108 1-METHYLQUINOLIN -2(1H)-ONE hsa [129] 
4QSU X-ray (1.9) SM+Q981-R1108 THYMINE hsa [129] 
4QSV X-ray (1.9) SM+Q981-R1108 THYMIDINE  hsa [129] 
4QSW X-ray (1.8) SM+Q981-R1108 5-methyluridine hsa [129] 
4QSX X-ray (1.9) SM+Q981-R1108 1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl] -5-
methylpyrimidine-2,4(1H,3H)-dione 
hsa [129] 
4QUT X-ray (1.7) SM+Q981-R1108 - hsa [130] 
4QUU X-ray (1.8) SM+Q981-R1108 - hsa [130] 
4TT2 X-ray (2.5) SM+Q981-R1108 - hsa [131] 
4TT4 X-ray (2.7) SM+Q981-R1108 - hsa [131] 
4TT6 X-ray (2.0) SM+Q981-R1108 - hsa [131] 
4TTE X-ray (1.8) SM+Q981-R1108 methyl 3-amino-5-(3,5-dimethyl-1,2-oxazol-4-yl)benzoate hsa [131] 
4TU4 X-ray (1.7) SM+Q981-R1108 3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-
[(phenylsulfonyl)amino]benzoic acid 
hsa [131] 
4TU6 X-ray (2.3) SM+Q981-R1108 - hsa [131] 
4TYL X-ray (1.9) SM+Q981-R1108 5-amino-1,3,6-trimethyl-1,3-dihydro-2H-benzimidazol-2-one hsa [124] 
4TZ2 X-ray (1.7) SM+Q981-R1108 3-(5-phenyl-4H-1,2,4-triazol-3-yl)aniline hsa [124] 
4TZ8 X-ray (2.2) SM+Q981-R1108 2-amino-7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-
c]azepin-4-one 
hsa [124] 
5A5N X-ray (2.0) SM+Q981-R1108 (2S)-2,6-diacetamido-N-methyl-hexanamide hsa [125] 
5A5O X-ray (2.0) SM+Q981-R1108 3-METHYL-1,2-DIHYDROQUINOLIN-2-ONE hsa [125] 
5A5P X-ray (2.0) SM+Q981-R1108 8-[2-(dimethylamino)ethylamino]-3-methyl-1,2-
dihydroquinolin-2-one 
hsa [125] 
5A5Q X-ray (2.0) SM+Q981-R1108 3-methyl-8-[(piperidin-4-yl)amino]-1,2-dihydro-1,7-
naphthyridin-2-one 
hsa [125] 











5A81 X-ray (2.0) SM+Q981-R1108 (3R,4R)-3-(cyclohexylmethoxy)piperidin-4-yl]amino}-3-
methyl-1,2-dihydro-1,7-naphthyridin-2-one 
hsa [126] 












6CPS X-ray (1.9) GPL+Q981-R1108 4-(2-HYDROXYETHYL)-1-PIPERAZINE 
ETHANESULFONIC ACID 
hsa [132] 
6HDN X-ray (1.9) SM+Q981-R1108 3-methyl-8-((8-methyl-8-azabicyclooctan-3-yl)amino)-1,7-
naphthyridin-2(1H)-one 
hsa [133] 




6S55 X-ray (2.1) SM+Q981-R1108 N-(4-bromo-3-((3-methylpiperidin-1-yl)sulfonyl)phenyl)-2-
(2,5-dioxoimidazolidin-1-yl)acetamide 
hsa [134] 




6S57 X-ray (1.8) SM+Q981-R1108 N-(3-(azepan-1-ylsulfonyl)-4-methylphenyl)-2-(4,4-dimethyl-
2,5-dioxoimidazolidin-1-yl)acetamide 
hsa [134] 
6YB4 X-ray (1.9) SM+Q981-R1108 N-(4-bromo-3-(3-methylpyrrolidin-1-yl)sulfonyl)phenyl)-2-(-
4-cyclopropyl-4-methyl-2,5-dioxoimidazolidin-1-yl)acetamide 
hsa [135] 











Figure 10. Overlay of the binding site of phenyl sulfonamide (cyan, PDB code 6S55) and KAc 
(yellow, PDB code 5A5N). The four conserved water molecules (PDB code 5A5N) are presented 
as red spheres. 
Compound 23 (GSK8814) retained the favorable ATAD2 interactions of the sulfone and 
selectivity over the BETs yet resulted in a dramatic improvement in logD and passive 
permeability. Inspired by the different conformation f piperidine in ATAD2 and BRD4 BD1, 
further optimization by an orthogonal conformational restriction strategy showed potent and 
selective tropane inhibitors (such as compound 24 with 60-fold selectivity) [133]. The tropane 
derivatives were, however, less selective than their disubstituted piperidine analogues 
(compound 23 with 500-fold selectivity) and much less selective than the corresponding 
compounds with SO2 group (1,300-fold selectivity). Thereafter, the phenylsulfonamides were 
identified as ATAD2 inhibitors by high-throughput screening [134]. Compound 25 has the most 
potent inhibition with single-digit micromolar IC50 (pIC50 5.0-6.0) in the ATAD2 TR-FRET 
assay. Optimization of compound 25 led to compound 26, which showed sub-micromolar 
ATAD2 inhibition and at least 10-fold selectivity over the BET bromodomains, such as CECR2, 
TAF1 and BRPF3. Using compound 26 as the starting point,  further optimization toward 
ATAD2 and CECR2 (cat eye syndrome chromosome region, ca didate 2) gave GSK232 (27), 
which showed high selectivity, cellular penetration, a d excellent physicochemical properties 
[135]. The phenyl sulfonamides exhibited a novel mode of binding to non-bromodomain and 
non-BET bromodomains through displacement of a normally conserved network of four water 
molecules (Figure 10).  
2.4 Spastin  
Like other AAA+ ATPases, there is an AAA domain in spastin, which is composed of a 
nucleotide-binding domain (NBD) and a four-helix bundle domain (HBD) [136, 137] (Figure 
11). Walker A (P-loop) motif and walker B (Switch II) motif at NBD are involved in ATP 
hydrolysis. The hydrophobic region (HR) at the other side of MIT possibly forms an 
intramembrane hairpin loop. The microtubule interacting and trafficking (MIT) domain at N-
terminal is connected to the AAA domain by a flexible linker containing a putative microtubule 
binding domain (MTBD) that binds to tubulin in ATP-independent manner [136]. Spastin is 
identified as a novel target of the multi-functional homeodomain interacting protein kinase 2 
(HIPK2) [138]. Knockdown of spastin in zebrafish leads to shorter axons in both branchiomotor 
and spinal motor neurons [139]. Overexpression of spastin decreases the density of cellular 
microtubules [140]. The defining feature of the AAA proteins is a structurally conserved AAA 
domain which assembles into an oligomer.  Chemical ross-linking and gel filtration 










 Spastazoline (28 in Figure 12A) is an ATP-competitive chemical inhibitor of human 
spastin with IC50 of 99 nM [142]. Its parent compound, compound 29, has an IC50 of 4.4 ± 2.1 
µM against Hs-spastin. It only inhibited one of the65 kinases tested (NTRK1) by 50%. It did not 
appreciably inhibit any of the four related AAA proteins including Xl-katanin, Hs-FIGL1, Mm-
VCP, or Hs-PCH2 at 10 µM. Spastazoline inhibits intercellular bridge disassembly by interfering 
with spastin activity, as the inhibitor-dependent phenotype was observed in wild-type cells but 
not in cells expressing the inhibitor resistance-conferring allele of spastin. 
 The mutant N527C did not disturb spastin’s ATPase activity. Based on the co-crystal 
structure of spastin-AAA-WT with compound 29 (Figure 12B), the authors designed compound 
30 for targeting spasin N527C. Compound 30 showed 20-fold less potency for WT spastin (IC50 
= 4.84 ± 1.46 µM) and 3-fold more potency for spastin N527C (IC50 = 0.23 ± 0.11 µM). The 
docking study of compound 30 with WT spastin showed compounds 29 and 30 shared the 
similar conformations at the binding site. The electron-withdrawing property and the unfavored 
angle (~112o) between F···C=O may decrease the binding affinity of compound 30 to WT 
spastin (Figure 12C). However, the N527A, -S, and -T mutant constructs are inhibited ~15-100 
fold less potently than N527C, which is likely due to favorable stereoelectronic interactions of 
the fluorine atom with the Cys527 residue [143]. Furthermore, two similar inhibitors (compound 
31 and 32, Figure 12A) were identified by the RADD (resistance analysis during design) 
involved in engineering point mutations in the target to generate active alleles. The 
superimposition of compounds 31 and 32 from crystal tructures showed the core, phenyl(1H-
1,2,4-triazol-1-yl)methanone, occupied the same sit and the substituents on 1,2,4-triazol ring 
were facing the opposite direction (Figure 12D). [144]. 
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Figure 11. (A) Schematic diagram of the spastin domain organization. (B) The top view of 












2.5 Midasin and Dynein 
Midasin (Mdn1, REA1) is an essential AAA (ATPase Associated with various Activities) 
protein that removes assembly factors from distinct precursors of the ribosomal 60S subunit. 
Mdn1 was involved in 28S rRNA maturation [145, 146]. Knockdown of Mdn1 by small 
interfering RNA (siRNA) resulted in a severe growth defect in HeLa cells. Mdn1 is assembled 
by six non-equivalent AAA domains linked in a single polypeptide, which are similar to those of 
the microtubule-based motor protein dynein [147-149] (Figure 13). The ATPase activity of 
AAA2, AAA3, AAA4, and AAA5 and ATP-binding ability of AAA6 are likely essential for 
Mdn1’s cellular functions [150]. However, the AAA domains in Mdn1 share <15% identity with 
those in dynein. 
Ribozinoindoles (or Rbins) were identified as potent, reversible, and specific inhibitors of 
Midasin [150]. Ribozinoindole-1 (Rbin-1, 33 in Figure 14) was discovered from a 10,353-
member library of diverse chemicals aiming for a chemical synthetic lethal screen, which was 
more toxic to the MDR-sup cells that contained a mutation in cut2, compared to those with a 
wild-type cut2+ or a mutation in cut1. The structural optimization of Rbin-1 (GI50 = 136 ± 7 nM) 
led to Rbin-2 with a GI50 of 14 ± 1 nM. Rbin-2 (34 in Figure 14) does not strongly suppress the 




Figure 12. (A) Chemical structure of 28-32. (B) The binding site of compound 29 on 
spastin with a vacuum electrostatic surface (PDB code 6NYV). (C) The superimposition of 
compounds 29 and 30 in the binding site (PDB code 6NYV). Compounds 29 and 30 are 
presented as yellow and cyan sticks, respectively. (D)The superimposition of compound 31 
(PDB code 6P10) and compound 32 (PDB code 6P12) at the binding site of spastin. 
Compound 31 and 32 are presented as green sticks and cyan lines, respectively. The key 









conferring mutation (mdn1-F1093L), indicating the physiological target of Rbins is Mdn1. The 
inhibition of Rbin-1 against Mdn1 led to the accumulation of pre-60S particles in Fission yeast 
cells.  
Dynein is a family of cytoskeletal motor proteins that regulates ciliary trafficking [151], 
mitotic spindle formation [152], and organelle transport [153]. Although dynein was discovered 
50 years ago, the research progress in understanding dynein has been slow due to its huge size 
and complicated structure. The motor domain is located t the dynein heavy chain and composed 
of an N-terminal mechanical linker, a central ring of six AAA+ modules, and a long stalk 
extending from the AAA+ ring with a microtubule-bindi g domain (MTBD) at the tip (Figure 
13). The tail is associated with accessory proteins and binds various cargoes. Although there are 
six AAA+ modules, only four AAA+ modules containing P-loops have nucleotide-binding sites 
[154]. The first site, AAA1, is the major site for ATP hydrolysis [155], whereas the other three 
P-loop containing AAA+ domains (AAA2-4) are thought to play a regulatory role. AAA3 can 
also hydrolyze ATP at a speed that is an order of magnitude slower than AAA1 [156]. Dynein 
transports various cellular cargos, provides forces and displacements important in mitosis, and 
drives the beat of eukaryotic cilia and flagella. Two of dynein’s ATPase sites contribute to the 
overall ATP hydrolysis and directional transport activity [157]. 
Ciliobrevins are the first specific small-molecule antagonists of cytoplasmic dynein. 
Starting from a high-throughput screen for inhibitors f the Hedgehog (Hh) pathway [158], a key 
mediator of embryonic development and oncogenesis [159], HPI-4, namely Ciliobrevin A, was 
discovered to block Hh pathway activation in cells lacking the negative regulator Suppressor of 
Fused (Sufu) [158]. Both ciliobrevins A and D (Figure 14, 35 and 36) induced ciliary Gli2 levels 
comparable to that in Shh-N-stimulated cells. Ciliobrevin D reversibly disrupts bipolar spindles, 
chromosomes, and the pre-formed spindles of metaphase-arrested cells and reduces overall 
microtubule levels [160]. Ciliobrevins are specific, reversible inhibitors of disparate cytoplasmic 
dynein-dependent processes.  
Ciliobrevins do not perturb cellular mechanisms that are independent of dynein function, 
including actin cytoskeleton organization and signaling pathways of the mitogen-activated 
protein kinase as well as phosphoinositol-3-kinase. Ciliobrevins, therefore, will be useful 
reagents for studying cellular processes that requi this microtubule motor and may guide the 
development of additional AAA ATPase superfamily inhibitors. The studies indicate that 
ciliobrevins can inhibit both cytoplasmic dynein 1 and 2, and, accordingly, the compounds will 
be broadly applicable probes of dynein-dependent processes [160]. Further development of 
ciliobrevin-like molecules could lead to isoform-selective inhibitors of this minus-end-directed 
microtubule motor and perhaps specific antagonists of other AAA1 ATPase superfamily 
members. 
Dynarrestin (37 in Figure 14) is a novel inhibitor of cytoplasmic dyneins 1 and 2 [161]. 
Dynarrestin inhibits Hh-dependent signaling and proliferation of primate and human tumor cells. 
It also inhibits cytoplasmic dynein 1-dependent processes at 25 µM, including endosome 
movement, mitosis, and microtubule gliding without inducing mitochondrial toxicity or having 
off-target effects on protein kinases. Dynarrestin reversibly inhibits dynein 1 without affecting 














Figure 14. Chemical structure of 33 - 37 
3. Conclusions and future perspectives 
AAA ATPases are essential for many cellular functions, and members of the AAA family 
are found in all organisms. To understand the role of each in cellular and molecular level, 
specific and selective small molecular inhibitors with distinct mode of action will be critical. 
Interestingly, the protein abundance for AAA ATPase is relatively high, for example p97/VCP is 
1% of total cellular proteins. To knock out essential proteins is not feasible and to knock down 
abundant proteins is more challenging. Therefore, t develop small molecule compounds provide 
a valuable tool to study biology of these protein and the added values of potentially validating 
whether these proteins are good drug targets and eventually to develop a drug. For example, p97 
is the most studied AAA ATPase, and due to the potent activity of p97 inhibition and the binding 
site, CB-5083 and NMS-873 could serve as tool compounds to further investigate p97 function 
and develop novel p97 inhibitors. CB-6644 as the RUVBL1/2 complex inhibitor showed 
promising activity and could serve as a tool compound for the further investigation on 
Figure 13. (A) Schematic diagram of the Midasin and dynein. (B) Crystal structure of 
Midasin (PDB code 6YLH) and dynein (PDB code 4RH7). Midasin: N domain, AAA 
domains, Tail, and MIDAS are presented in blue, redgreen, and pink, respectively. Dynein: 
Tail, Linker, AAA domains, Stalk, C domain, and MTBD are presented in gray, orange, red, 










RUVBL1/2 complex function and signaling pathway. Due to the significance of AAA ATPases, 
the work done so far provides the foundation for identification and development of new 
inhibitors against AAA ATPases using the combination of chemical biology, structural biology, 
and proteomic approaches in the near future. 
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